Pegylated interferon

Pegylated interferon (PEG-IFN) is a form of interferon used in the treatment of chronic hepatitis C and hepatitis B. The medication is designed to be absorbed slowly, allowing for a longer duration of therapeutic effect.

Mechanism of Action

Pegylated interferon works by stimulating the body's immune system to fight off viral infections. It binds to specific receptors on the surface of cells, triggering a cascade of immune responses that inhibit viral replication and promote the clearance of infected cells.

Pharmacokinetics

The pegylation process, which involves the attachment of polyethylene glycol (PEG) to the interferon molecule, increases the size of the molecule and reduces its clearance from the body. This results in a longer half-life and allows for less frequent dosing compared to standard interferon.

Clinical Use

Pegylated interferon is primarily used in the treatment of chronic hepatitis C and B. It is often used in combination with other antiviral drugs, such as ribavirin, to increase the likelihood of achieving a sustained virologic response (SVR).

Side Effects

Common side effects of pegylated interferon include flu-like symptoms, depression, fatigue, and hematologic abnormalities such as neutropenia and thrombocytopenia. Severe side effects can include autoimmune disorders, psychiatric symptoms, and cardiovascular or pulmonary complications.

Contraindications

Pegylated interferon is contraindicated in patients with decompensated liver disease, autoimmune hepatitis, and in those with a history of severe psychiatric disorders. It should be used with caution in patients with cardiac disease.

See Also

• Interferon
• Hepatitis C
• Hepatitis B
• Ribavirin

References

‎